Cite
HARVARD Citation
Assassi, S. et al. (2022). Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial. ACR open rheumatology. 4 (10), pp. 837-844. [Online].